论文信息 - Optimal Bayesian-feasible dose escalation for cancer phase I trials

Optimal Bayesian-feasible dose escalation for cancer phase I trials

We present an adaptive dose escalation scheme for cancer phase I clinical trials which is based on a parametric quantal response model. The dose escalation is Bayesian-feasible, Bayesian-optimal and consistent. It is designed to approach the maximum tolerated dose as fast as possible subject to the constraint that the predicted probability of assigning doses higher than the maximum tolerated dose is equal to a specified value.

[1] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.

[2] R. Tsutakawa. Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response Curve , 1980 .

[3] S. Zacks,et al. Sequential Search of Optimal Dosages: The Linear Regression Case. , 1973 .

[4] S. Zacks,et al. Sequential Search of an Optimal Dosage, I , 1973 .

[5] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[6] S. Zacks,et al. 5 Adaptive designs for parametric models , 1996, Design and analysis of experiments.

[7] J B Greenhouse,et al. Bayesian methods for phase I clinical trials. , 1992, Statistics in medicine.

[8] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.